Dr. Jordan Dubow, Chief Medical Officer, Avadel Pharmaceuticals, intent on improving drug delivery technology, is focusing on narcolepsy, a disease that causes severe excessive sleepiness and in many cases cataplexy.  While there seems to be a genetic predisposition for narcolepsy, like many neurological diseases, this rare disease is difficult to diagnose with medicines that treat daytime sleepiness and cataplexy episodes presenting significant limitations.  Avadel’s once-nightly FT218 is an extended release long acting version of sodium oxybate that treats both features of the disease and allows patients to get a full night sleep without need for middle of the night dosing.